Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer

Keiichi Koshizuka; Daiju Sakurai; Miki Sunagane; Yukiyoshi Mita; Sawako Hamasaki; Takeshi Suzuki; Naoko Kikkawa; Michiyo Nakano; Toyoyuki Hanazawa

doi:10.22541/au.160438152.20129058/v1

loading page

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer

Keiichi Koshizuka,
Daiju Sakurai,
Miki Sunagane,
Yukiyoshi Mita,
Sawako Hamasaki,
Takeshi Suzuki,
Naoko Kikkawa,
Michiyo Nakano,
Toyoyuki Hanazawa

Abstract

Nivolumab is used for patients with recurrent/metastatic head and neck cancer resistant to platinum. We report a 76-year-old man with squamous cell carcinoma of the tongue, who developed toxic epidermal necrolysis (TEN) after nivolumab treatment. TEN is a fatal disease, and early treatment of the adverse events are important.

01 Nov 2020Submitted to Clinical Case Reports

Show details

Hide details

03 Nov 2020Submission Checks Completed

03 Nov 2020Assigned to Editor

07 Nov 2020Reviewer(s) Assigned

18 Nov 2020Review(s) Completed, Editorial Evaluation Pending

01 Dec 2020Editorial Decision: Revise Minor

02 Dec 20201st Revision Received

04 Dec 2020Submission Checks Completed

04 Dec 2020Assigned to Editor

04 Dec 2020Review(s) Completed, Editorial Evaluation Pending

09 Dec 2020Editorial Decision: Accept

Feb 2021Published in Clinical Case Reports volume 9 issue 2 on pages 848-852. 10.1002/ccr3.3695

Abstract

Peer review status:Published